Researchers at the University of Colorado Anschutz have published a proof-of-concept study. Fertility and infertility This demonstrates that injectable semaglutide may provide meaningful reproductive benefits for women with polyendocrine-metabolic ovary syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).
This report is the first to examine how semaglutide injections can improve reproductive outcomes in women with PMOS while also addressing obesity and metabolic dysfunction. Researchers evaluated participants enrolled in the ongoing CU Anschutz-led RESTORE clinical trial. This clinical trial is investigating the role of semaglutide in restoring ovulation and improving reproductive health in adolescents and adults with PMOS.
Women with PMOS often face a frustrating choice between treatments that target reproductive symptoms and those that address metabolic health. Our early study results suggest that semaglutide injection may improve both and provide a more comprehensive care approach. If someone responds with a 10% weight loss, this drug is incredibly promising. ”
Melanie Cree, MD, professor at Anschutz University and lead author of the report
Cree is also a pediatric endocrinologist at Children’s Hospital Colorado.
PMOS is a complex endocrine-metabolic disease characterized by irregular menstrual cycles, elevated testosterone levels, infertility risk, and increased obesity and cardiometabolic disease. Existing treatments such as metformin and hormonal contraceptives often fail to adequately address both reproductive and metabolic complications simultaneously.
The proof-of-concept analysis focused on a subset of participants aged 12 to 35 who achieved at least 10% weight loss during treatment. The researchers said they saw faster-than-expected improvements in fertility during the trial, prompting the research team to report preliminary results while the larger study continues.
“What makes this study particularly important is that it specifically focuses on women with PMOS who receive semaglutide injections,” Cree says. “GLP-1 therapeutics have revolutionized obesity treatment, but there is still a critical need for rigorous data examining how these treatments impact fertility and reproductive function in this population.”
The RESTORE study is currently evaluating semaglutide treatment in girls and women with PMOS and obesity, with the overarching goal of determining whether weight loss and improved metabolism restore ovulation and improve reproductive outcomes. The trial continues to enroll and track participants.
The authors note that their paper is an initial proof-of-concept analysis and that larger, longer-term studies are needed to confirm the persistence of the observed reproductive effects. However, the findings provide encouraging evidence that injectable semaglutide may emerge as a promising treatment option for women with PMOS seeking to improve both their metabolic and reproductive health.
sauce:
University of Colorado Anschutz
Reference magazines:
Cree, MG, others. (2026). Weight loss associated with semaglutide use is associated with improved reproductive indicators in PMOS: a proof-of-concept analysis. Fertility and infertility. DOI: 10.1016/j.fertnstert.2026.06.002. https://www.fertstart.org/article/S0015-0282(26)00478-4/abstract
